ABEO
Income statement / Annual
Last year (2023), Abeona Therapeutics Inc.'s total revenue was $3.50 M,
an increase of 147.52% from the previous year.
In 2023, Abeona Therapeutics Inc.'s net income was -$54.19 M.
See Abeona Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$3.50 M
|
$1.41 M
|
$3.00 M
|
$10.00 M
|
$0.00
|
$3.00 M
|
$837,000.00
|
$889,000.00
|
$1.04 M
|
$925,000.00
|
| Cost of Revenue |
$1.07 M |
$450,000.00 |
$4.46 M |
$30.14 M |
$8.68 M |
$38.70 M |
$16.99 M |
$10.66 M |
$0.00 |
$0.00 |
| Gross Profit |
$2.44 M |
$964,000.00 |
-$1.46 M |
-$20.14 M |
-$8.68 M |
-$35.70 M |
-$16.15 M |
-$9.77 M |
$1.04 M |
$925,000.00 |
| Gross Profit Ratio |
0.7 |
0.68 |
-0.49 |
-2.01 |
0 |
-11.91 |
-19.3 |
-10.99 |
1 |
1 |
| Research and Development
Expenses |
$31.09 M
|
$28.97 M
|
$34.33 M
|
$30.14 M
|
$48.57 M
|
$38.70 M
|
$16.99 M
|
$10.66 M
|
$4.72 M
|
$333,000.00
|
| General & Administrative
Expenses |
$19.00 M
|
$17.26 M
|
$22.80 M
|
$23.78 M
|
$20.71 M
|
$20.11 M
|
$10.94 M
|
$13.29 M
|
$14.32 M
|
$3.71 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$19.00 M
|
$17.26 M
|
$22.80 M
|
$23.78 M
|
$20.71 M
|
$20.11 M
|
$10.94 M
|
$13.29 M
|
$14.32 M
|
$3.71 M
|
| Other Expenses |
$0.00 |
$141,000.00 |
$3.25 M |
$4.59 M |
$7.82 M |
$2.36 M |
$741,000.00 |
$825,000.00 |
$551,000.00 |
$3.72 M |
| Operating Expenses |
$17.94 M |
$46.22 M |
$60.37 M |
$58.50 M |
$77.09 M |
$61.16 M |
$28.67 M |
$24.77 M |
$19.59 M |
$4.06 M |
| Cost And Expenses |
$50.64 M |
$46.67 M |
$60.37 M |
$58.50 M |
$77.09 M |
$61.16 M |
$28.67 M |
$24.77 M |
$19.59 M |
$4.06 M |
| Interest Income |
$2.12 M |
$431,000.00 |
$69,000.00 |
$1.30 M |
$1.21 M |
$1.51 M |
$525,000.00 |
$2.01 M |
$4.03 M |
$45,000.00 |
| Interest Expense |
$418,000.00 |
$736,000.00 |
$3.67 M |
$4.12 M |
$400,000.00 |
$11,000.00 |
$8,000.00 |
$6,000.00 |
$6,000.00 |
$582,000.00 |
| Depreciation &
Amortization |
$3.20 M
|
$4.58 M
|
$4.46 M
|
$5.60 M
|
$8.68 M
|
$2.36 M
|
$741,000.00
|
$825,000.00
|
$551,000.00
|
$11,000.00
|
| EBITDA |
-$50.57 M
|
-$34.38 M
|
-$76.80 M
|
-$74.52 M
|
-$67.61 M
|
-$54.31 M
|
-$26.58 M
|
-$21.05 M
|
-$13.97 M
|
-$26.19 M
|
| EBITDA Ratio |
-14.45 |
-31.6 |
-18.02 |
-4.26 |
0 |
-18.11 |
-31.74 |
-23.67 |
-13.43 |
-3.32 |
| Operating Income Ratio
|
-13.47
|
-32.01
|
-29.95
|
-8.14
|
0
|
-19.4
|
-33.26
|
-26.86
|
-17.83
|
-3.38
|
| Total Other
Income/Expenses Net |
-$7.05 M
|
$11.22 M
|
$4.90 M
|
-$2.81 M
|
$808,000.00
|
$1.50 M
|
$517,000.00
|
$2.01 M
|
$4.02 M
|
-$23.65 M
|
| Income Before Tax |
-$54.19 M |
-$39.70 M |
-$84.94 M |
-$84.23 M |
-$76.28 M |
-$56.67 M |
-$27.32 M |
-$21.87 M |
-$14.53 M |
-$26.78 M |
| Income Before Tax Ratio
|
-15.48
|
-28.07
|
-28.31
|
-8.42
|
0
|
-18.9
|
-32.64
|
-24.6
|
-13.97
|
-28.95
|
| Income Tax Expense |
$0.00 |
-$7.89 M |
$3.67 M |
$4.12 M |
$400,000.00 |
$1.51 M |
$525,000.00 |
$2.01 M |
$4.03 M |
$582,000.00 |
| Net Income |
-$54.19 M |
-$31.81 M |
-$88.61 M |
-$88.35 M |
-$76.68 M |
-$56.67 M |
-$27.32 M |
-$21.87 M |
-$14.53 M |
-$26.78 M |
| Net Income Ratio |
-15.48 |
-22.5 |
-29.54 |
-8.83 |
0 |
-18.9 |
-32.64 |
-24.6 |
-13.97 |
-28.95 |
| EPS |
-2.53 |
-4.05 |
-22.5 |
-23.84 |
-38.07 |
-29.81 |
-16.4 |
-16 |
-13.16 |
-344.56 |
| EPS Diluted |
-2.53 |
-4.05 |
-22.5 |
-23.84 |
-38.07 |
-29.81 |
-16.4 |
-16 |
-13.16 |
-344.56 |
| Weighted Average Shares
Out |
$21.38 M
|
$7.86 M
|
$3.94 M
|
$3.71 M
|
$2.01 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.10 M
|
$77,716.00
|
| Weighted Average Shares
Out Diluted |
$21.38 M
|
$7.86 M
|
$3.94 M
|
$3.71 M
|
$2.01 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.10 M
|
$77,716.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
